Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism

Semin Thromb Hemost. 2020 Oct;46(7):772-776. doi: 10.1055/s-0040-1710337. Epub 2020 May 11.

Author

Sam Schulman^{1

2}

Affiliations

¹ Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
² Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

No abstract available

Publication types

Review

MeSH terms

Anticoagulants / administration & dosage
Anticoagulants / therapeutic use
Betacoronavirus*
Biomarkers
C-Reactive Protein / analysis
COVID-19
Coronavirus Infections / blood*
Coronavirus Infections / complications
Cytokines / blood
Fibrin Fibrinogen Degradation Products / analysis
Heparin, Low-Molecular-Weight / administration & dosage
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Inflammation
Intensive Care Units / statistics & numerical data
Pandemics*
Platelet Count
Pneumonia, Viral / blood*
Pneumonia, Viral / complications
SARS-CoV-2
Sepsis / blood
Sepsis / complications
Thrombophilia / blood
Thrombophilia / drug therapy
Thrombophilia / etiology*
Venous Thromboembolism / epidemiology
Venous Thromboembolism / etiology*
Venous Thromboembolism / prevention & control

Substances

Anticoagulants
Biomarkers
Cytokines
Fibrin Fibrinogen Degradation Products
Heparin, Low-Molecular-Weight
fibrin fragment D
C-Reactive Protein